"A Hearty Debate" Concludes Plant-Based Meat Alternatives Are Healthier for Your Heart than Meat

Even though there is substantial variability in the contents and nutritional profiles of plant-based meat alternatives (PBMAs), the nutritional profiles tend to reflect a heart-healthy dietary pattern. A review article 新しいタブ／ウィンドウで開く appearing in the Canadian Journal of Cardiology 新しいタブ／ウィンドウで開く, published by Elsevier, of the available studies directly comparing the impact of plant-based and animal-based meats consistently suggests that the plant-based alternatives improve cardiovascular risk factors.  PBMAs are highly processed plant-based food products that typically replace meat in the diet. In Canada, the growing demand for PBMAs coincides with public health recommendations to reduce ultra-processed food consumption, which prompts the need to investigate the long-term health implications of PBMAs.  Lead author Matthew Nagra, ND, Vancouver, BC, Canada, says, "While the plant-based meat market has experienced significant growth in recent years and more and more Canadians are enjoying plant-based burgers, surprisingly little is known about how these meat alternatives may impact health and in particular cardiovascular disease risk. Thus, we sought to review the available literature on the topic to identify what is currently known and to provide direction for future research."  The authors of the article reviewed the research published from 1970 to 2023 on PBMAs, their contents, nutritional profiles, and impact on cardiovascular disease risk factors, such as cholesterol levels and blood pressure. Their analysis shows:  

• There is substantial variability in the contents and nutritional profiles of PBMAs. 

• On average, PBMAs tend to have a more heart-healthy nutritional profile than meat, although the high sodium content of some products may be of concern. 

• PBMAs have been shown to improve some cardiovascular risk factors, including cholesterol levels, in several randomized controlled trials. 

• PBMAs have not been shown to raise blood pressure, despite the high sodium content of some products. 

• There is currently a lack of long-term research evaluating how these alternatives may affect the risk of developing a heart attack or stroke. 

• There is currently little research on the healthfulness of some common components of PBMAs, such as vital wheat gluten (seitan). 

The authors of the review article were surprised to find that there is a near complete lack of research on vital wheat gluten, which is the primary protein source incorporated into many popular PBMAs, and cardiovascular risk factors. 

Dr. Nagra continues, “Further, the lack of research on cardiovascular outcomes as of 2023 is shocking, given that there are randomized controlled trials evaluating risk factors dating back to 1990. More detailed research is needed in light of the increasing consumption of PBMAs and our lack of knowledge of how these products impact risk.” 

In an accompanying editorial 新しいタブ／ウィンドウで開く, J. David Spence, CM, MD, FRCPC, FAHA, Professor Emeritus of Neurology & Clinical Pharmacology, Western University, and Director, Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, London, ON, Canada, notes, "In an excellent review of PBMAs, Nagra et al. focus on reduction of cardiovascular risk factors, and the effects of various individual dietary factors on cardiovascular risk." 

However, Professor Spence points out that, "What really matters is not the effect of individual components of a diet, nor the effect of diet on cardiovascular risk factors; it is the effect of diet on the actual risk of cardiovascular events such as myocardial infarction and stroke. Most physicians markedly underestimate the cardiovascular benefit of diet and place far too little emphasis on diet in the management of patients at high risk of cardiovascular events."

Senior author of the review article Ehud Ur, MB, FRCPC, Professor, Division of Endocrinology & Metabolism, University of British Columbia, Vancouver, BC, Canada, concludes, "For those looking to reduce their meat intake, especially if it’s red meat, replacing that with PBMAs is likely a heart-healthy choice. For those who already limit their meat intake, PBMAs can be incorporated into a healthy dietary pattern as an excellent protein source; however, it may be beneficial to choose options that are lower in saturated fat and sodium if consuming them regularly."

Finally, Dr. Spence adds a note of caution regarding the dietary implications of egg consumption, saying, "Persons at risk of cardiovascular disease should limit meat intake and avoid egg yolk, so plant-based meat substitutes and egg substitutes are helpful to patients wishing to reduce their cardiovascular risk. Their effect on reducing actual cardiovascular risk is undoubtedly much greater than their effect on cardiovascular risk factors."

Notes for editors 

The article is “Animal vs Plant-Based Meat: A Hearty Debate,” by Matthew Nagra, ND, Felicia Tsam, RHN, Shaun Ward, MSc, and Ehud Ur, MB, FRCPC (https://doi.org/10.1016/j.cjca.2023.11.005 新しいタブ／ウィンドウで開く).  

The article is openly available for 30 days at https://www.onlinecjc.ca/article/S0828-282X(23)01882-2. 

Journalists wishing to speak to the authors should contact Felicia Tsam at [email protected] 新しいタブ／ウィンドウで開く. 

The editorial is "Reducing Cardiovascular Risk: The Potential of Plant-Based Meat Alternatives and Egg Substitutes," by J. David Spence, CM, MD, FRCPC, FAHA (https://doi.org/10.1016/j.cjca.2023.12.026 新しいタブ／ウィンドウで開く).  

The article is openly available for 30 days at https://www.onlinecjc.ca/article/S0828-282X(23)02042-1. 

Journalists wishing to speak to the authors should contact Prof. David Spence at [email protected] 新しいタブ／ウィンドウで開く. 

Both articles appear online ahead of the Canadian Journal of Cardiology, volume 40, issue 7, (July 2024) published by Elsevier.  

Full text of the articles is also available to credentialed journalists upon request. Contact Astrid Engelen at +31 6 14395474 or [email protected] 新しいタブ／ウィンドウで開く for a copy of the PDFs or more information.  

About the Canadian Journal of Cardiology 

The Canadian Journal of Cardiology 新しいタブ／ウィンドウで開く is the official journal of the Canadian Cardiovascular Society 新しいタブ／ウィンドウで開く. It is a vehicle for the international dissemination of new knowledge in cardiology and cardiovascular science, particularly serving as a major venue for the results of Canadian cardiovascular research and Society guidelines. The journal publishes original reports of clinical and basic research relevant to cardiovascular medicine as well as editorials, review articles, case reports, and papers on health outcomes, policy research, ethics, medical history, and political issues affecting practice. www.onlinecjc.ca 新しいタブ／ウィンドウで開く

About the Editor-in-Chief 

Editor-in-Chief Stanley Nattel, MD, is Paul-David Chair in Cardiovascular Electrophysiology and Professor of Medicine at the University of Montreal and Director of the Electrophysiology Research Program at the Montreal Heart Institute Research Center. 

About the Canadian Cardiovascular Society (CCS) 

The CCS 新しいタブ／ウィンドウで開く is the national voice for cardiovascular clinicians and scientists, representing more than 2,300 cardiologists, cardiac surgeons and other heart health specialists across Canada. We advance heart health for all by setting standards for excellence in heart health and care, building the knowledge and expertise of the heart team, and influencing policy and advocating for the heart health of all Canadians. For further information on the CCS visit https://www.ccs.ca 新しいタブ／ウィンドウで開く. 

エルゼビアについて エルゼビアは、科学情報と分析を牽引するグローバル企業として、研究者や医療従事者が社会の利益のために科学を進歩させ、医療成果を向上させることを支援しています。我々は信頼できるエビデンスベースのコンテンツと高度なAI対応デジタルテクノロジーに基づくソリューションにより、インサイトと重要な意思決定を促進することでこれを実現しています。

エルゼビアは、140 年以上にわたり研究および医療コミュニティの活動を支援してきました。全世界で 2,500 人以上の技術者を含む 9,500 人の従業員がおり、重要な職務における研究者や、図書館員、アカデミックリーダー、資金提供者、政府機関、R&D 関連企業、医師、看護師、将来の医療従事者や教育者を支援することに従事してきました。2,900 誌以上の科学ジャーナルと代表的な参考文献には、Cell Press、The Lancet、Gray's Anatomy など、各分野の主要なタイトルを含みます。 エルゼビア・ファウンデーション 新しいタブ／ウィンドウで開くと共に、開発途上国および世界中の科学、研究、医療分野におけるインクルージョン＆ダイバーシティを推進するため、支援コミュニティと連携して活動しています。 エルゼビアは、プロフェッショナルおよびビジネス顧客向けの情報に基づく分析および意思決定ツールのグローバルプロバイダーである RELX 新しいタブ／ウィンドウで開くグループの一部です。業務内容やデジタルソリューション、コンテンツ詳細については、 www.elsevier.com/ja-jpをご参照ください。